Literature DB >> 24264645

[Diagnosis and therapy of late onset Pompe disease].

A Schüller1, C Kornblum, M Deschauer, M Vorgerd, B Schrank, E Mengel, Z Lukacs, D Gläser, P Young, U Plöckinger, B Schoser.   

Abstract

As Pompe disease glycogen storage disease type 2 with a severely reduced life expectancy is now a treatable disorder, accurate diagnostic procedures and evidence-based indications for therapy are mandatory. We screened the literature for consensus reports and published trial data of late-onset Pompe disease. These data were summarized in a Delphi consensus method approach. The clinical suspicion of late-onset Pompe disease should be substantiated by the validated dry blood spot test measurement for acid α-glucosidase activity. Alternatively, enzyme activity analysis in lymphocytes is also feasible. Glucosidase α gene sequencing for verifying the diagnosis is recommended. A muscle biopsy including measurements of acid α-glucosidase activity and glycogen concentration is warranted for differential diagnosis in selected cases. The confirmed diagnosis should lead to a multidisciplinary treatment approach, possibly including enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24264645     DOI: 10.1007/s00115-013-3947-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  27 in total

1.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.

Authors:  Thomas P Mechtler; Susanne Stary; Thomas F Metz; Víctor R De Jesús; Susanne Greber-Platzer; Arnold Pollak; Kurt R Herkner; Berthold Streubel; David C Kasper
Journal:  Lancet       Date:  2011-11-29       Impact factor: 79.321

Review 2.  Diagnosis of glycogenosis type II.

Authors:  B Bembi; E Cerini; C Danesino; M A Donati; S Gasperini; L Morandi; O Musumeci; G Parenti; S Ravaglia; F Seidita; A Toscano; A Vianello
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

3.  Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.

Authors:  C I van Capelle; N A M E van der Beek; M L C Hagemans; W F M Arts; W C J Hop; P Lee; J Jaeken; I M E Frohn-Mulder; P J F M Merkus; D Corzo; A C Puga; A J Reuser; A T van der Ploeg
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

Review 4.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

5.  Sleep-disordered breathing and respiratory failure in acid maltase deficiency.

Authors:  U Mellies; R Ragette; C Schwake; M Baethmann; T Voit; H Teschler
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

6.  Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II.

Authors:  Bruno Bembi; Federica Edith Pisa; Marco Confalonieri; Giovanni Ciana; Agata Fiumara; Rossella Parini; Miriam Rigoldi; Arrigo Moglia; Alfredo Costa; Annalisa Carlucci; Cesare Danesino; Maria Gabriela Pittis; Andrea Dardis; Sabrina Ravaglia
Journal:  J Inherit Metab Dis       Date:  2010-09-14       Impact factor: 4.982

7.  Toward deconstructing the phenotype of late-onset Pompe disease.

Authors:  Angela Schüller; Stephan Wenninger; Nicola Strigl-Pill; Benedikt Schoser
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

8.  Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.

Authors:  B G H Schoser; J Müller-Höcker; R Horvath; K Gempel; D Pongratz; H Lochmüller; W Müller-Felber
Journal:  Neuropathol Appl Neurobiol       Date:  2007-06-15       Impact factor: 8.090

9.  Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale.

Authors:  M L C Hagemans; P Laforêt; W J C Hop; I S J Merkies; P A Van Doorn; A J J Reuser; A T Van der Ploeg
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

Review 10.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

View more
  3 in total

1.  Multiple, Successful Pregnancies in Pompe Disease.

Authors:  Ursula Plöckinger; Nikolaus Tiling; Lenka Bosanska; Bettina Temmesfeld-Wollbrueck; Kerstin Irlbacher; Viktor Mezger; Gabriele Gossing
Journal:  JIMD Rep       Date:  2015-11-17

2.  2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.

Authors:  U Plöckinger; V Prasad; A Ziagaki; N Tiling; A Poellinger
Journal:  Hum Genomics       Date:  2018-03-09       Impact factor: 4.639

Review 3.  Recent developments in blood glucose sensors.

Authors:  Hui-Chen Wang; An-Rong Lee
Journal:  J Food Drug Anal       Date:  2015-02-14       Impact factor: 6.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.